Track topics on Twitter Track topics that are important to you
The purpose of this study is to develop markers for use of placebo vaginal products and measure markers of mucosal semen exposure among healthy women. The study will also monitor safety of placebo product use.
This is a Phase I, non-randomized, open label study in healthy, non-pregnant, HIV negative women, who are not at risk of pregnancy, and are at low risk for STIs (sexually transmitted infections). Participants will be assigned to use one of four placebo products: IVR (intravaginal ring) (approximately 20 participants), and vaginal insert, film or HEC universal placebo gel (approximately 10 participants each). Each woman will provide pre-product use vaginal swabs. Participants assigned to vaginal insert, film or gel will use products with and without timed intercourse with their male partner for a total of two doses of the product, will provide vaginal swabs post product use, and will be seen over 4 visits.
Participants assigned to IVR do not have to be sexually active with a male partner. IVR assigned participants will use a total of 3 IVRs, one at a time. IVR assigned participants will use the first IVR (IVR1) for approximately 24 - 36 hours (no exposure to semen during IVR1 use). IVR assigned participants will use a second IVR (IVR2) for approximately 7 - 10 days and a third IVR (IVR3) for approximately 28 - 32 days. During the use of IVR2 and IVR3, participants may engage in sexual intercourse, but it is not required. Women assigned to IVR use will be seen over 5 visits.
Once a woman completes the study cycle with one study product, she may elect to do another cycle using a different product after a wash-out period of at least 7 days, if she can comply with study product specific protocol requirements. She may elect to do up to four cycles, each with a different study product. For each cycle, V1 screening procedures will be repeated as indicated by symptoms and or participant history, as assessed by the investigator and as outlined in the study manual. If re-screening procedures are not indicated, the new cycle may start with Visit 2 (V2).
At Visit 1 (V1), volunteers will be consented and undergo procedures to confirm they are eligible to continue in the study. Participants will be counseled to refrain from vaginal activity, as applicable, for 48 hours prior to V2.
V2 should occur on days 3 - 10 of the menstrual cycle, or for participants who do not have regular menstrual cycles, when the participant is not having heavy menstrual bleeding. Once it has been confirmed that the participant meets all of the inclusion criteria and none of the exclusion criteria, baseline pre-product use vaginal swabs will be taken. Participants will be required to refrain from any vaginal activity until after Visit 3 (V3).
- Participants assigned to gel, film or insert, will insert one dose (Dose 1) vaginally in the clinic. Vaginal swabs will be obtained in the clinic approximately 15 minutes after product use. Participants will be given vaginal swabs for home use. Participants will be instructed to obtain vaginal swabs, at bedtime daily, for 7 days, starting at the first bedtime after V2. Vaginal swabs will be stored in the participant's refrigerator and returned to the clinic at V3. V3 will occur 7 - 10 days after V2.
- For participants assigned to the IVR, the IVR1 will be inserted by the participant in the clinic. The participant will leave IVR1 in place until V3, which will occur 24 - 36 hours after V2.
- Participants assigned to gel, film or insert will return used vaginal swabs to the clinic. Additional vaginal swabs will be obtained in the clinic. Participants will vaginally insert one dose of their assigned product (Dose 2) in the clinic. Vaginal swabs will be obtained in the clinic approximately 15 minutes after product use. The participants will be instructed to have vaginal intercourse with her male sexual partner within approximately 12 hours (± 4 hours) after insertion of the product. They will obtain vaginal swabs, at bedtime daily, for 7 days, starting at the first bedtime after V3 and after timed intercourse, as above. Participants will be instructed to refrain from additional acts of vaginal intercourse or other vaginal activity until Visit 4 (V4). Vaginal swabs will be stored in the participant's refrigerator and returned to the clinic at V4. V4 will occur 7 - 10 days after V3.
- For participants assigned to the IVR, IVR1 will be removed at this visit. Post IVR1 use vaginal swabs will be obtained in the clinic. The second IVR (IVR2) will be inserted by the participant in the clinic. The participant will be instructed to leave the IVR2 in place until V4, which will occur 7 - 10 days after V3. IVR Participants may have vaginal intercourse (not required) during the use of IVR2 but should not have any other vaginal activity during the use of IVR2.
- Participants assigned to gel, film or insert will return used vaginal swabs to the clinic. Additional vaginal swabs will be obtained in the clinic. Participants will be exited from the study at this visit or they may elect to use a different study product.
- For participants assigned to the IVR, IVR2 will be removed at this visit. Post IVR2 use vaginal swabs will be obtained in the clinic. The third IVR (IVR3) will be inserted by the participant in the clinic. The participant will leave IVR3 in place until Visit 5 (V5), which will occur 28 - 32 days after V4. Participants may have vaginal intercourse (not required) during the use of IVR3 but should not have any other vaginal activity during the use of IVR3.
At V5 (For IVR only):
• IVR3 will be removed at this visit. Post IVR3 use vaginal swabs will be obtained in the clinic. Participants will be exited from the study at this visit or they may elect to use a different study product.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label
HEC Placebo gel, Placebo Intravaginal Ring, Placebo Vaginal Film, Placebo Vaginal Insert
Eastern Virginia Medical School
Not yet recruiting
Published on BioPortfolio: 2015-10-08T09:53:24-0400
The purpose of The Quatro Study is to assess the acceptability, preferences, user experience and effect on sexual behavior of four different vaginal microbicide or multi-purpose technology...
This prospective, randomized, single-blinded, placebo controlled trial will examine the safety and pharmacokinetics (PK) of a polyurethane tenofovir disoproxil fumarate (TDF) vaginal ring ...
IPM 018 is a double-blind, randomized, placebo-controlled study conducted at one site in Belgium among 24 healthy, HIV-negative women to evaluate dapivirine release for 28 days from matrix...
The purpose of the study is to evaluate the safety, pharmacokinetics and pharmacodynamics of, and the tolerability and acceptance of an intravaginal ring (IVR) delivering both tenofovir an...
This is a phase I randomized trial assessing the safety of a single vaginal placebo film application. In order to develop a vaginal film which can provide extended release of an Antiretrov...
Placebo beverage conditions remain a key element in the methodological toolkit for alcohol researchers interested in evaluating pharmacological and nonpharmacological factors influencing the effects o...
Different to spirituality, the placebo-effect is well operationalized. Against this background, an attempt is made to look at a possible phenomenological relationship between the therapeutic effective...
Which progesterone vaginal pessary dose regimen induces adequate secretory transformation of the endometrium, in comparison with progesterone vaginal gel and placebo?
One in three clinical trial patients with major depressive disorder report symptomatic improvement with placebo. Strategies to mitigate the effect of placebo responses have focused on modifying study ...
Among movement disorders and medicine in general, PD is one of the conditions for which there is a greater knowledge of the placebo and nocebo responses. In other movement disorders, the knowledge of ...
Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.
An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.
Use of a device (film badge) for measuring exposure of individuals to radiation. It is usually made of metal, plastic, or paper and loaded with one or more pieces of x-ray film.
A film base coated with an emulsion designed for use with x-rays.
The uptake of substances from the VAGINA via the vaginal epithelium/mucosa.
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...